SHPH — Shuttle Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Brief: Shuttle Pharma Completes Clinical Trial Site Enrollment For Phase 2 Of Ropidoxuridine For Treatment Of Patients With Glioblastoma
Brief: Shuttle Pharma To Enroll Patients In Phase 2 Clinical Trial Of Ropidoxuridine
Brief: Shuttle Pharma Appoints Timothy Lorber As Chief Financial Officer
Brief: Shuttle Pharma Announces Its Intent To Pursue A Rights Offering
Brief: Shuttle Pharmaceuticals Submits IND Application To The US FDA For Ropidoxuridine Phase II Clinical Trial For Patients With Glioblastoma
Brief: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program
Brief: Shuttle Pharma Announces Results Of Pre-Ind Meeting With FDA For Ropidoxuridine Phase Ii Clinical Trial For Patients With Glioblastoma
Brief: Shuttle Pharma Expands Patent Coverage On HDAC Inhibitor Platform
Brief: Shuttle Pharma's Selective Hdac6 Inhibitor Shown To Stimulate Innate Immune Response In Pre-Clinical Studies
Brief: Shuttle Pharmaceuticals Completes Manufacturing Of Active Pharmaceutical Ingredient For Use In Clinical Trial
Brief: AFH Holding & Advisory LLC Reports 9.14% Passive Stake In Shuttle Pharmaceuticals
Brief: Shuttle Pharmaceuticals Holdings Inc On May 25 Filed Form 10-Q With SEC, As A Result Regained Compliance With Nasdaq Listing Rules
Brief: Shuttle Pharmaceuticals Provides Q1 2023 Corporate Update
Brief: Shuttle Pharmaceuticals Enters Research Agreement With Georgetown University For Testing Of Small Molecule Radiation Sensitizers And Immune Activation Candidates
Brief: Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
Brief: Shuttle Pharmaceuticals Expands Laboratory Space To Advance Drug Development Pipeline, Diagnostic Capabilities
Shuttle Pharma rises after $4.3 mln private placement
Brief: Shuttle Pharmaceuticals Announces Private Placement Of $4.3 Million Of Senior Secured Convertible Note And Warrants
Brief: Shuttle Pharmaceuticals Manuscript Published In Cancer Research Communications